UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs

UroGen Pharma Ltd. (NASDAQ:URGN) is 1 of the best small-cap biotech stocks to bargain according to analysts.

On November 6, 2025, UroGen Pharma Ltd. (NASDAQ:URGN) reported its Q3 2025 results, highlighting beardown maturation successful request alongside its dependable commercialized expansion. Furthermore, preliminary October figures indicated that request gross much than doubled compared to the erstwhile 3 months. This maturation reflects the expanding adoption of physicians amid operational delays. The institution closed the 4th with $127.4 cardinal successful currency and marketable securities.

As the imperishable billing codification takes effect successful aboriginal 2026, UroGen Pharma Ltd. (NASDAQ:URGN) anticipates a smoother process, contempt merchandise uptake perchance facing administrative lags of up to 60 days owed to reimbursement and coding complexities. Furthermore, the institution noted an enlargement of its income unit to 82 representatives. With this expansion, the institution strengthened doc outreach and diligent entree crossed large payers, with sum accounting for implicit 95% of insured lives.

The 4th saw UroGen Pharma Ltd. (NASDAQ:URGN)’s nett nonaccomplishment widen from $23.7 cardinal successful Q3 2024 to $33.3 million, driven by rising R&D expenses and delayed gross recognition. Looking ahead, the institution appears to beryllium successful a coagulated position, focusing connected optimizing diligent onboarding and accelerating reimbursement cycles, which is good supported by the maturation successful merchandise request noted successful October. UroGen provided gross guidance for lone JELMYTO, expecting $94 cardinal to $98 cardinal successful nett revenues for the afloat year.

UroGen Pharma Ltd. (NASDAQ:URGN) focuses connected processing and selling specialty crab treatments, delivering targeted, minimally invasive therapies.

While we admit the imaginable of URGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.